(Q37877123)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21593751%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

review article

1 reference

title

Rosiglitazone and the risk of adverse cardiovascular outcomes (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21593751%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21593751%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

author name string

A G Winterstein

series ordinal

1

1 reference

24 August 2017

language of work or name

English

0 references

publication date

1 June 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21593751%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacology & Therapeutics

1 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21593751%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

volume

89

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21593751%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21593751%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

page(s)

776-778

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21593751%20AND%20SRC:MED&resulttype=core&format=json

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

1 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.43

Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.43

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.43

Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.43

Regulatory Action on Rosiglitazone by the U.S. Food and Drug Administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.43

Recent trials in hypertension: compelling science or commercial speech?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.43

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/CLPT.2011.43

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21593751%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

1 reference